Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database

Francini, Edoardo; Montagnani, Francesco; Nuzzo, Pier Vitale; Gonzalez-Velez, Miguel; Alimohamed, Nimira S.; Cigliola, Antonio; Moreno, Irene; Rubio, Jaime; Crivelli, Francesca; Shaw, Grace; Petrioli, Roberto; Bengala, Carmelo; Francini, Guido; Foncillas, Jesus Garcia; Sweeney, Christopher; Higano, Celestia S.; Bryce, Alan Haruo; Harshman, Lauren Christine; Lee-Ying, Richard; Heng, Daniel Yick Chin

doi:10.1200/JCO.2020.38.6_suppl.30

https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.6_suppl.30

Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database / Francini, E., Montagnani, F., Nuzzo, P.V., Gonzalez-Velez, M., Alimohamed, N.S., Cigliola, A., Moreno, I., Rubio, J., Crivelli, F., Shaw, G., Petrioli, R., Bengala, C., Francini, G., Foncillas, J.G., Sweeney, C., Higano, C.S., Bryce, A.H., Harshman, L.C., Lee-Ying, R., Heng, D.Y.C.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - 38:(2020), pp. 30-30. [10.1200/JCO.2020.38.6_suppl.30]